EP0452753A1 - Im Wesentlichen monomeres normales menschliches Serum-Albumin - Google Patents
Im Wesentlichen monomeres normales menschliches Serum-Albumin Download PDFInfo
- Publication number
- EP0452753A1 EP0452753A1 EP91105453A EP91105453A EP0452753A1 EP 0452753 A1 EP0452753 A1 EP 0452753A1 EP 91105453 A EP91105453 A EP 91105453A EP 91105453 A EP91105453 A EP 91105453A EP 0452753 A1 EP0452753 A1 EP 0452753A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- albumin
- product
- suspension
- aluminum
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to therapeutic compositions comprising novel formulations and processes to obtain a purer and safer preparation of Normal Serum Albumin (Human) essentially free of aluminum and other intoxicants.
- Certain formulations herein described permit substantially extended dating periods for at least the following three reasons: 1) absence of heavy molecular weight components, 2) the removal of aluminum and other contaminants, and 3) the purity (100%). Labeled levels remain constant throughout the dating period.
- albumin as a therapeutic is well known.
- One such product is "PLASBUMIN" 25% and 5% (Cutter Biological, Miles Inc., Berkeley, California). Many have sought to improve albumin preparations, and it has been shown that some have achieved some level of improved composition. But each in some manner lacks attributes of this novel composition. For example: One manufacturer of albumin reduces the level of aluminum to as low as 96 ppb. During the 40 degree centigrade stability testing of that product, the level increased to as much as 380 ppb. This patent teaches the methods necessary to process source plasma (human) through to an albumin preparation with superior shelf life and with demonstrated labeled values which do not change during the dating period.
- This invention addresses the use of albumin sources which are essentially low hemoglobin containing such as Source Plasma (Human) as described in the Federal Register.
- the method of this invention and the novel invention products can be albumin originating from genetically engineered sources such as rDNA produced sources and other essentially low hemoglobin containing albumin sources.
- the major source of albumin in the world today is plasma, the method of preparing these compositions will be primarily related to plasma or serum. It is not, for example, directed to hemoglobin containing placenta source preparations.
- Many methods have been known for recovering purified albumin for infusion from materials containing hemoglobin such as placenta utilized as the starting material. See U.S. Patent 4,197,238 which also provides a survey of methods. See also U.S.
- Patent 4,169,829 also directed to purified albumin prepared from placental or other hemolyzed blood containing hemoglobin.
- the novelty of this present invention teaches that monomeric albumin (greater than 99%), being 100% pure by cellulose acetate electrophoresis and free from all residual processing chemicals, can be provided using the method taught in this present invention.
- the preparation contains essentially no material of a molecular weight greater than dimer albumin.
- a preparation free of polymerized protein, manufactured from an essentially hemoglobin free albumin source such as Source Plasma (Human), and essentially free from aluminum is heretofore unknown.
- Source Plasma Human
- An object of this invention is to provide a long shelf life albumin.
- a further object of this invention is to provide an economical and safe procedure and product, comprising albumin as the major component, useable in medical treatment, from sources essentially free of hemoglobin as a starting material. The ability of this composition to remain essentially free of aluminum permits lasting label levels throughout the dating period of this therapeutic.
- the method of manufacture may commence with an albumin source such as the Cohn albumin fractionation scheme at some point relevant to the Fraction V or crude albumin step.
- the source may also be in-process upstream systems, such as Cohn Fraction IV-1 and Cohn Fraction IV-4. Thin film evaporation techniques may be used to reduce cumbersome volume streams. See Cohn et al. J. Am. Chem. Soc. 68, 459 (1946).
- the Fraction V precipitate or more purified Cohen Fraction state is suspended in water, which may be approximately three volumes more or less of cold, pyrogen free, distilled water.
- the temperature of the water is below room temperature and may be preferably 8°C plus or minus 4°. A solution kept at this temperature is formed by thorough mixing.
- the pH is determined and, if necessary, is adjusted so that it should be in the range of 4.5 ⁇ 0.2.
- the ideal and most preferable pH for this step is 4.5 to 4.6.
- the pH must always be below 5.0.
- the albumin is filtered through a depth filter such as is available from AMF Cuno Corp. The filter media must be of such depth that substantially all lipidic proteinaceous material is removed from the starting solution.
- the albumin filtrate pH is then adjusted to the approximate isoelectric range of ⁇ globulins (approximately pH 5.0 to 6.0; preferably, 5.3) with a dilute base solution such as 1.0 Molar sodium carbonate or 1.0 Molar sodium hydroxide. Any convenient base buffering system may be utilized to accomplish the elevation of pH.
- the system at the above described temperature is prepared to undergo a heat shock.
- a quantity of sodium caprylate is added to the system based on the protein concentration of the system during heat shock, i.e., for each kilo of protein available in the filtrate, approximately 30 grams of sodium caprylate is introduced into the system.
- Ethanol such as SDA-3A alcohol is added to the stabilized albumin filtrate on a per volume basis to equal from approximately 10% to 20% alcohol.
- the preferred temperature elevation is to 50°C. This temperature is maintained for a period of at least one hour, and the preferred range is approximately one to three hours.
- the system temperature may be reduced to normal plasma processing temperatures, such as less than about 10°C.
- DEAE Sephadex Pharmacia Inc.
- the purified albumin filtrate pH is then adjusted from approximately 6.0 to about 8.5 (most preferably 7.2).
- the purified albumin is then loaded on an ultrafilter such as that built by Romicon, Inc., or the Koch Co.
- the albumin solution is diafiltered, and the volume replacement is accomplished using a weak salt solution such as 3% sodium chloride or sodium acetate or in some cases sodium caprylate solutions most preferably sodium chloride.
- the purified albumin solution is diafiltered, and as a result of displacement of the salts, the aluminum and other contaminants are removed. A diafiltration against water (most preferably four volumes of cold distilled water) is performed.
- the purified, washed albumin is harvested from the ultrafiltration equipment at such a concentration to yield the desired protein level allowing for the addition of excipients.
- the preferred composition of the final product prepared in the above method would have a molarity of caprylate based on the albumin concentration.
- a 25% protein preparation would be stabilized generally at from 0.02 Molar to approximately 0.1 Molar, and preferentially, a molarity of 0.04 caprylate.
- Original preparations of E. J. Cohn were "salt poor".
- the composition of choice of this present invention would contain approximately 0.1 Molar aminoacetic acid to guarantee tonicity in the event of slight dilutions. This resulting composition will have the greatest shelf life and retention of biological activity.
- the preparation described in this disclosure if desired, might be finally compounded with 0.02 Molar sodium caprylate and 0.02 Molar acetyl-dl-tryptophan with sodium chloride to achieve 130 to 160 mEq/L of sodium.
- the presence of tryptophan in the albumin causes the product to darken with age, and there may be some concern for the products of tryptophan degradation.
- Fraction V solution was then passed through the filter housing, and a filtrate of less than 10 National Turbidity Units (Hach Nephelometer, Loveland, Colorado) was collected.
- the filter housing was rinsed with +5°C distilled water in the amount to displace the soluble protein from the filter media. Determinations were made to confirm the recovery of better than 98% of the protein originally suspended.
- the filtrate pH was 4.66.
- the pH of the filtrate was adjusted to 5.15 using 1.0 Molar sodium carbonate. Based on the amount of albumin protein present, 30 grams of sodium caprylate per kilo of Fraction V paste were added, followed by the addition of 181 grams of SDA3A alcohol for each liter of albumin filtrate being processed.
- the temperature of the alcoholic albumin filtrate was then elevated to 50°C and held at this temperature for 2 hours.
- the heat shocked material was then chilled to 8°C.
- One gram of DEAE Sephadex (Pharmacia) was added for each liter of material.
- a Cuno filter as described above was utilized to remove the denatured globulins and the insoluble DEAE Sephadex (Pharmacia) that had just been added.
- the filtrate was analyzed for recovered protein and found to contain 97% of the starting available protein.
- the solution turbidity was less than 10 National Turbidity Units.
- the ultra pure albumin filtrate pH was adjusted to 7.22, using 1.0 Molar sodium carbonate.
- the filtrate was then loaded on a pilot model ultrafilter equipped with PM 30 Romicon hollow fiber ultrafilter cartridges (a product of Rohm & Hass). Three volume exchanges were made using 3% simple saline. Permeate flux rates were very good, and rates over 200 mL/cartridge/per minute were common. Five volume exchanges were then performed using cold distilled water. Product temperatures were always held at less than 10°C. The product was concentrated and harvested from the ultrafilter. The protein concentration was determined to be 26.5%, and the product turbidity was less than 5 National Turbidity Units. There is some concern that the caprylate used during the heat shock would bind to the albumin and an excessive amount of caprylate would create a problem.
- Neat samples of the product were heated at 60°C and were found to gel within 10 minutes which demonstrated the reduction of caprylate from the heat shock to a level of no concern. Samples were compounded into a final container configuration as described above, and the table explains the test results.
- Figure I comprises the albumin level of albumin of this invention ( ⁇ ) compared to commercial albumin (+) in accelerated time study at 40°C both stored in aluminum containing containers.
- Figure II compares the aluminum level of albumin of this invention with aluminum level of commercially available albumin of various manufacturers A through E.
- Figure III compares the heavy molecular weight components in the albumin of this invention with the heavy molecular weight components of commercially available albumin of various manufactures A through E, all measured by High Pressure Liquid Chromatography (HPLC).
- HPLC High Pressure Liquid Chromatography
- Figure IV compares the purity of the albumin of this invention compared to the purity of commercially available albumin of various manufactures A through E all measured by Cellulose Acetate Electrophoresis (CAE).
- Figure V compares the turbidity level of the albumin of this invention with the turbidity level of commercially available albumin of various manufactures A through E all measured in National Turbidity Units (NTU) on a Hach Nephelometer.
- NTU National Turbidity Unit
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51136290A | 1990-04-19 | 1990-04-19 | |
US511362 | 1990-04-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0452753A1 true EP0452753A1 (de) | 1991-10-23 |
EP0452753B1 EP0452753B1 (de) | 2004-06-23 |
Family
ID=24034566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91105453A Expired - Lifetime EP0452753B1 (de) | 1990-04-19 | 1991-04-06 | Methode zur Herstellung von im Wesentlichen monomeren normalen menschlichen Serum-Albumin |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0452753B1 (de) |
JP (2) | JP3009242B2 (de) |
AT (1) | ATE269872T1 (de) |
CA (1) | CA2040036A1 (de) |
DE (1) | DE69133399T2 (de) |
ES (1) | ES2224094T3 (de) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05317079A (ja) * | 1992-05-20 | 1993-12-03 | Green Cross Corp:The | 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物 |
EP0696595A1 (de) * | 1994-08-10 | 1996-02-14 | Bayer Corporation | Fraktionierung des Albumins bei niedriger Temperatur unter Verwendung von Sodiumcaprylat als Trennwirkstoff |
ES2103236A1 (es) * | 1996-01-30 | 1997-09-01 | Grifols Grupo Sa | Albumina humana terapeutica con baja capacidad para la fijacion de aluminio. |
US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
US5849874A (en) * | 1991-07-12 | 1998-12-15 | Gist-Brocades, N.V. | Process for the purification of serum albumin |
EP0933083A1 (de) * | 1991-07-12 | 1999-08-04 | Dsm N.V. | Verfahren zur Reinigung von Serumalbumin |
WO1999062936A1 (en) * | 1998-06-01 | 1999-12-09 | Genentech, Inc. | Separation of protein monomers from aggregates by use of ion-exchange chromatography |
EP0976765A1 (de) * | 1998-07-10 | 2000-02-02 | Centeon Pharma GmbH | Verfahren zur Herstellung einer Proteinlösung |
WO2000056768A2 (en) * | 1999-03-19 | 2000-09-28 | Bayer Corporation | Chromatographic albumin process |
EP2048234A1 (de) | 1999-01-30 | 2009-04-15 | Novozymes Biopharma UK Limited | Chromatographisches Verfahren zur Reinigung von Albumin |
WO2016207353A1 (en) * | 2015-06-26 | 2016-12-29 | Ferring B.V. | Methods of purification and/or viral inactivation |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003040798A (ja) * | 2001-07-26 | 2003-02-13 | Nihon Pharmaceutical Co Ltd | 低アルミニウム含有アルブミン製剤およびその製造法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1196636A (en) * | 1967-03-01 | 1970-07-01 | Ustav Ser A Ockovacich Latek O | Process for the Preparation of Pure Albumins from Normal and Haemolysed Sera and Plasma |
US3926939A (en) * | 1973-08-24 | 1975-12-16 | Mikhail Ivanovich Ivanov | Method of extracting pure serum albumin from biological fluids using a salt of a carboxylic aliphatic acid |
US4156681A (en) * | 1974-03-28 | 1979-05-29 | Plasmesco Ag | Process for isolating albumin from blood |
US4228154A (en) * | 1979-02-26 | 1980-10-14 | Armour Pharmaceutical Company | Purification of plasma albumin by ion exchange chromatography |
EP0121468A2 (de) * | 1983-04-01 | 1984-10-10 | Rhone-Poulenc Recherches | Verfahren zur Zerlegung von Blutplasma |
EP0249483A2 (de) * | 1986-06-13 | 1987-12-16 | Green Cross Corporation | Verfahren für die Produktion von im wesentlichen reinem Albumin |
-
1991
- 1991-04-06 AT AT91105453T patent/ATE269872T1/de not_active IP Right Cessation
- 1991-04-06 EP EP91105453A patent/EP0452753B1/de not_active Expired - Lifetime
- 1991-04-06 ES ES91105453T patent/ES2224094T3/es not_active Expired - Lifetime
- 1991-04-06 DE DE69133399T patent/DE69133399T2/de not_active Expired - Lifetime
- 1991-04-09 CA CA002040036A patent/CA2040036A1/en not_active Abandoned
- 1991-04-16 JP JP3110900A patent/JP3009242B2/ja not_active Expired - Lifetime
-
1999
- 1999-10-19 JP JP11296909A patent/JP2000095798A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1196636A (en) * | 1967-03-01 | 1970-07-01 | Ustav Ser A Ockovacich Latek O | Process for the Preparation of Pure Albumins from Normal and Haemolysed Sera and Plasma |
US3926939A (en) * | 1973-08-24 | 1975-12-16 | Mikhail Ivanovich Ivanov | Method of extracting pure serum albumin from biological fluids using a salt of a carboxylic aliphatic acid |
US4156681A (en) * | 1974-03-28 | 1979-05-29 | Plasmesco Ag | Process for isolating albumin from blood |
US4228154A (en) * | 1979-02-26 | 1980-10-14 | Armour Pharmaceutical Company | Purification of plasma albumin by ion exchange chromatography |
EP0121468A2 (de) * | 1983-04-01 | 1984-10-10 | Rhone-Poulenc Recherches | Verfahren zur Zerlegung von Blutplasma |
EP0249483A2 (de) * | 1986-06-13 | 1987-12-16 | Green Cross Corporation | Verfahren für die Produktion von im wesentlichen reinem Albumin |
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 112, No. 5, 29 January 1990, Columbus, Ohio, USA; MIKULA, I. et al.: "Method of albumin isolation", page 299; left-hand column; Ref. No. 32966, Abstract. * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6831157B2 (en) | 1991-07-12 | 2004-12-14 | Dsm Ip Assets B.V. | Process for the purification of serum albumin |
US6504011B1 (en) | 1991-07-12 | 2003-01-07 | Dsm N.V. | Process for the purification of serum albumin |
US6150504A (en) * | 1991-07-12 | 2000-11-21 | Dsm Patents & Trademarks | Process for the purification of serum albumin |
US5849874A (en) * | 1991-07-12 | 1998-12-15 | Gist-Brocades, N.V. | Process for the purification of serum albumin |
EP0933083A1 (de) * | 1991-07-12 | 1999-08-04 | Dsm N.V. | Verfahren zur Reinigung von Serumalbumin |
JPH07102148B2 (ja) * | 1992-05-20 | 1995-11-08 | 株式会社ミドリ十字 | 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物 |
JPH05317079A (ja) * | 1992-05-20 | 1993-12-03 | Green Cross Corp:The | 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物 |
US6034221A (en) * | 1992-09-23 | 2000-03-07 | Delta Biotechnology Limited | High purity albumin |
US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
US7601515B2 (en) | 1994-06-27 | 2009-10-13 | Novozymes Biopharma Uk Limited | Process of high purity albumin production |
KR100418821B1 (ko) * | 1994-08-10 | 2004-05-20 | 바이엘 코포레이션 | 분배제로서카프릴산나트륨을사용하는저온알부민분획법 |
EP0696595A1 (de) * | 1994-08-10 | 1996-02-14 | Bayer Corporation | Fraktionierung des Albumins bei niedriger Temperatur unter Verwendung von Sodiumcaprylat als Trennwirkstoff |
US7223561B2 (en) | 1995-05-25 | 2007-05-29 | Novozymes Delta, Limited | Process of high purity albumin production |
US5846930A (en) * | 1996-01-30 | 1998-12-08 | Grupo Grifols, S.A. | Therapeutic human albumin having a low aluminium binding capacity |
ES2103236A1 (es) * | 1996-01-30 | 1997-09-01 | Grifols Grupo Sa | Albumina humana terapeutica con baja capacidad para la fijacion de aluminio. |
EP0787498A3 (de) * | 1996-01-30 | 1998-10-21 | Grupo Grifols, S.A. | Menschliche therapeutische Albumin mit niedriger Aluminiumbindungsfähigkeit |
EP1413312A3 (de) * | 1996-01-30 | 2004-09-01 | Probitas Pharma, S.A. | Menschliches therapeutisches Albumin mit niedriger Aluminiumbindungsfähigkeit |
EP1413312A2 (de) * | 1996-01-30 | 2004-04-28 | Probitas Pharma, S.A. | Menschliches therapeutisches Albumin mit niedriger Aluminiumbindungsfähigkeit |
US6620918B2 (en) | 1998-06-01 | 2003-09-16 | Genentech, Inc. | Separation of polypeptide monomers |
EP1500661A1 (de) * | 1998-06-01 | 2005-01-26 | Genetech, Inc. | Trennung von Protein-Monomeren von Aggregaten mittels Ionaustausch-Chromatographie |
WO1999062936A1 (en) * | 1998-06-01 | 1999-12-09 | Genentech, Inc. | Separation of protein monomers from aggregates by use of ion-exchange chromatography |
EP0976765A1 (de) * | 1998-07-10 | 2000-02-02 | Centeon Pharma GmbH | Verfahren zur Herstellung einer Proteinlösung |
US9029102B2 (en) | 1999-01-30 | 2015-05-12 | Novozymes Biopharma Dk A/S | Process for the purification of recombinant albumin |
US9555344B2 (en) | 1999-01-30 | 2017-01-31 | Albumedix A/S | Process for the purification of recombinant albumin |
EP2048234A1 (de) | 1999-01-30 | 2009-04-15 | Novozymes Biopharma UK Limited | Chromatographisches Verfahren zur Reinigung von Albumin |
EP2272961A1 (de) | 1999-01-30 | 2011-01-12 | Novozymes Biopharma DK A/S | Verfahren zur Herstellung von rekombinantem Albumin mit reduzierter Mannosylierung |
US7993877B2 (en) | 1999-01-30 | 2011-08-09 | Novozymes Biopharma Dk A/S | Process for the purification of recombinant albumin |
WO2000056768A2 (en) * | 1999-03-19 | 2000-09-28 | Bayer Corporation | Chromatographic albumin process |
WO2000056768A3 (en) * | 1999-03-19 | 2001-01-04 | Bayer Ag | Chromatographic albumin process |
WO2016207353A1 (en) * | 2015-06-26 | 2016-12-29 | Ferring B.V. | Methods of purification and/or viral inactivation |
EP3628675A1 (de) * | 2015-06-26 | 2020-04-01 | Ferring B.V. | Verfahren zur aufreinigung und/oder vireninaktivierung |
RU2719468C2 (ru) * | 2015-06-26 | 2020-04-17 | Ферринг Б.В. | Способы очистки и/или вирусной инактивации |
US10906953B2 (en) | 2015-06-26 | 2021-02-02 | Ferring B.V. | Methods of purification and/or viral inactivation |
AU2016282916B2 (en) * | 2015-06-26 | 2022-01-20 | Ferring B.V. | Methods of purification and/or viral inactivation |
Also Published As
Publication number | Publication date |
---|---|
JPH0733800A (ja) | 1995-02-03 |
ATE269872T1 (de) | 2004-07-15 |
ES2224094T3 (es) | 2005-03-01 |
JP2000095798A (ja) | 2000-04-04 |
CA2040036A1 (en) | 1991-10-20 |
EP0452753B1 (de) | 2004-06-23 |
DE69133399D1 (de) | 2004-07-29 |
DE69133399T2 (de) | 2005-06-30 |
JP3009242B2 (ja) | 2000-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2155630C (en) | Low temperature albumin fractionation using sodium caprylate as a partitioning agent | |
US4216205A (en) | Process of preparing a serum protein composition for intravenous application | |
EP0073371B1 (de) | Intravenös injektierbares Globulin aus Immunserum und Verfahren zu seiner Herstellung | |
US5250663A (en) | Preparing essentially monomeric normal human serum albumin | |
US7879331B2 (en) | Ultra-high yield intravenous immune globulin preparation | |
EP0452753A1 (de) | Im Wesentlichen monomeres normales menschliches Serum-Albumin | |
EP1928915B1 (de) | Präparation von intravenösem immunglobulin mit ultrahoher ausbeute | |
KR101960729B1 (ko) | 감소된 수준의 용존 산소를 갖는 인간 알부민을 제조하는 방법 | |
EA022821B1 (ru) | Способ получения биологически активного рекомбинантного г-ксф человека | |
EP0469985A1 (de) | Verfahren zur Herstellung des Von Willebrand-Faktors von höchster Reinheit | |
ES2373035T3 (es) | Método para eliminar polímeros de seroalbúmina humana. | |
JPH0533239B2 (de) | ||
NO169875B (no) | Fremgangsmaate for fremstilling av et konsentrat av den anti-hemofile faktor viii | |
US4075197A (en) | Serum albumin production | |
JPH0381290A (ja) | 精製されたアルブミン溶液の製造方法 | |
JP2001500867A (ja) | 血漿タンパク質含有薬剤の製造方法 | |
WO2000067789A1 (en) | High concentration immunoglobulin preparation and method for its production | |
JP3054371B2 (ja) | アルミニウム結合能の低い治療用ヒトアルブミン | |
CA2150612A1 (en) | Process for producing albumin preparation | |
JP2001055340A (ja) | アルブミン製剤の製造方法 | |
NO145563B (no) | Fremgangsmaate for fremstilling av et renset konsentrat av faktor-viii. | |
RU2321421C2 (ru) | Обедненная прекалликреином альбуминовая фракция плазмы крови | |
JPH04234326A (ja) | アルブミン製剤及びその製法 | |
Gammelgaard et al. | Aluminium in human albumin solutions | |
US4791191A (en) | Depyrogenation of clinical albumin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19911202 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER CORPORATION |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER CORPORATION |
|
17Q | First examination report despatched |
Effective date: 19960724 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER CORPORATION |
|
TPAD | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOS TIPA |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 07K 14/765 A Ipc: 7C 07K 1/36 B |
|
RTI1 | Title (correction) |
Free format text: METHOD FOR PREPARING ESSENTIALLY MONOMERIC NORMAL SERUM ALBUMIN (HUMAN) |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER CORPORATION |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040623 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040623 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040623 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040623 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040623 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69133399 Country of ref document: DE Date of ref document: 20040729 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040923 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040923 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040923 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2224094 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050406 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20050324 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20100426 Year of fee payment: 20 Ref country code: FR Payment date: 20100506 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20100428 Year of fee payment: 20 Ref country code: DE Payment date: 20100428 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20100426 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69133399 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20110405 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20110405 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20110406 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20130718 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20110407 |